MediciNova, Inc.
NASDAQ:MNOVBiotechnology
-$0.02 today
- Market cap
- $68.14M
- Beta
- 0.62
- P/E (TTM)
- -5.6
- EPS (TTM)
- -$0.24
Volume 0.12M
Average 0.04M
MNOV Other Working Capital
Cash effect of changes in other operating assets and liabilities.
MediciNova, Inc.NASDAQ: MNOV
Other Working Capital · Q1 FY2026 · quarter ended Mar 2026
Other working capital dips below year-ago levels
Q1 FY2026 other working capital of $356.25K (cash outflow) fell 19.6% year over year, behind the +117.1% change in trailing-twelve-month other working capital. Sequentially, it fell 39.8% from the prior quarter. Over 3 fiscal years it compounded at +417.4% a year.
Context
- Other working capital amounted to 172.1% of revenue in FY2025.
- Other working capital increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -19.6% toward the trailing-twelve-month pace of +117.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Working Capital history
USD · from the cash flow
- Latest · FY2025
- 705.15K USD
- Year-over-year change
- +205.7%
| Period | Period end | Other Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 705.15K | +205.7% |
| FY2024 | 2024-12-31 | (667.21K) | -819.4% |
| FY2023 | 2023-12-31 | 92.75K | +1722.2% |
| FY2022 | 2022-12-31 | 5.09K | +102.8% |
| FY2021 | 2021-12-31 | (181.42K) | — |
Other Working Capital vs competitors
How MNOV compares with its peers on the latest reported figures
- MNOV's LTM Mar 2026 other working capital of $86.96K is the smallest of the 11 companies compared; the peer median is $668K.
- Its year-over-year change of +117.1% is the 4th highest of 11, against a peer median of -48.6%.
- Other working capital amounts to 14.6% of revenue for MNOV, versus a peer median of 24.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $8.16M | +273.8% | +12.1% | 89.3% | |
| LTM Mar 2026 | $6.51M | -4.9% | -59.0% | — | |
| LTM Mar 2026 | $3.71M | +222.5% | — | — | |
| LTM Mar 2026 | $2.31M | -77033.3% | — | — | |
| LTM Mar 2026 | $2.06M | +58.6% | +2.8% | 0.8% | |
CBUSCibus, Inc. | LTM Mar 2026 | $2.04M | -145.3% | — | 47.5% |
| LTM Mar 2026 | $1.75M | +147.5% | — | — | |
| LTM Mar 2026 | $743K | -92.3% | +8.4% | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $593K | -165.7% | +45.5% | — |
| LTM Mar 2026 | $150K | -105.8% | -24.2% | 0.2% | |
| LTM Mar 2026 | $86.96K | +117.1% | +417.4% | 14.6% | |
| Peer median (excluding MNOV) | $668K | -48.6% | +5.6% | 24.2% | |
Competitors are the stored peer set for MNOV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (10.13M) | (14.07M) | (8.57M) | (11.05M) | (12M) |
| Depreciation & Amortization | 26.15K | 17.71K | 20.3K | 21.08K | 20.1K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.72M | 642.52K | 710.71K | 1.19M | 829.1K |
| Change in Working Capital | (1.21M) | 334.1K | 111.99K | (979.56K) | 1.17M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (1.03M) | 329.01K | 19.24K | (312.35K) | 459.87K |
| Other Working Capital | (181.42K) | 5.09K | 92.75K | (667.21K) | 705.15K |
| Other Non-Cash Items | 216.93K | 163.19K | 297.49K | 173.32K | 173.68K |
| Operating Cash Flow | (9.38M) | (12.91M) | (7.43M) | (10.64M) | (9.81M) |
| Capital Expenditures | (28.73K) | (5.01K) | (21.3K) | (895) | 0 |
| Acquisitions (Net) | 0 | 5.01M | 0 | 0 | 0 |
| Purchases of Investments | 0 | (59.88M) | 0 | 0 | 0 |
| Sales of Investments | 0 | 19.88M | 39.93M | 0 | 0 |
| Other Investing Activities | 0 | (5.01M) | 0 | 198 | (2.9K) |
| Investing Cash Flow | (28.73K) | (40.01M) | 39.91M | (697) | (2.9K) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 20.89M | 7.92K | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (112.26K) | 0 | 0 | 0 | 244.02K |
| Financing Cash Flow | 20.78M | 7.92K | 0 | 0 | 244.02K |
| Effect of Forex Changes | 26.55K | (16.81K) | 17.27K | 3.96K | 15.68K |
| Net Change in Cash | 11.39M | (52.93M) | 32.49M | (10.64M) | (9.55M) |
| Free Cash Flow | (9.41M) | (12.92M) | (7.45M) | (10.64M) | (9.81M) |
MediciNova, Inc.
NASDAQ:MNOV
Intrinsic Alpha fair value
Locked
Current Price
$1.33
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.